

## Data Analysis Group

### *Membership*

**Co-Chair**

Professor Peter Collins

**Co-Chair**

Professor Charles Hay

**User representatives:**

Dr Ryan Cheal

Paul Sartain

Dr Richard Gorman

**UKHCDO members:**

Prof Pratima Chowdary

Dr Georgina Hall

Dr Dan Hart

Dr Ri Liesner

Dr Mary Mathias

Dr Martin Scott

Dr Susie Shapiro

Dr Kate Talks

**Haemophilia Nurses and physiotherapy representatives:**

Simon Fletcher

Dr David Stephensen

**National Haemophilia Database:**

Lynne Dewhurst

Ben Palmer

Dr Hua Xiang

Andrew McNally

### *Meetings*

The Data Analysis Group (DAG) is a subgroup of the Data Management Working Party. Its role is to assess and prioritise applications to analyse data held by NHD, including Haemtrack and joint score data. Applications are assessed based on data governance considerations, scientific merit and available resources. The group meets once a month by videoconference and meetings last on average 60-90 mins.

Requests for analyses are submitted on a standardised form. This form is available from NHD. The DAG particularly welcomes applications from UKHCDO working parties. All members of UKHCDO and UKHCDO working parties are encouraged to suggest analyses and are invited to collaborate with the DAG on these projects.

The DAG reviews and discusses all applications. It provides feedback to the applicant and works with them to refine the proposal, if necessary. The contributions from the user representatives have been particularly useful in assessing the applications and interpreting the results.

The data analyses that are generated from the requests are reviewed and commented on by the group and may be further revised, if necessary, before release. Reports often contain caveats about data limitations that impact on the interpretation of reports.

All reports are made available to UKHCDO members through the UKHCDO Collaborate website.

The DAG leads an investigator-led project funded by Roche/Chugai to analyse data held on the NHD relating to the introduction of Emicizumab in both the inhibitor and non-inhibitor groups. A paper

relating to the inhibitor cohort has been submitted and another reporting on the non-inhibitor cohort is under development.

Requests for data analyses have been submitted by individual members of UKHCDO, Haemophilia Centres to support service planning, UKHCDO working parties, Haemophilia physiotherapy group, NHS England, and pharmaceutical companies. The DAG has supported the development of a paper describing enhanced half-life factor VIII in the UK and this was published recently.

The DAG is open to new members from UKHCDO, and anyone interested should contact Charles Hay and Peter Collins.

Prof Peter Collins,  
Chair UKHCDO Data Management Working Party

Prof Charles RM Hay,  
Co-Director NHD

October 2021